Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 5, 2014

View Archived Issues

Gilead Sciences begins phase Ib study of GS-9883

Intra-Cellular Therapies and Takeda terminate collaboration to develop PDE1 inhibitors

Single nucleotide mutation in NFIA gene leads to brain malformation and urinary tract defect

Eisai advances pipeline in second quarter of fiscal 2014

Chemically attenuated whole parasite blood-stage malaria vaccine approach tested in humans

IntelGenx completes pilot study of INT-0036 for schizophrenia

Protection against T. cruzi observed with ArtinM in an acute experimental infection model

Affinivax launched with funding from Bill & Melinda Gates Foundation

Altor BioScience begins development of ALT-803 for multiple myeloma

Asana BioSciences reports discovery of kinase inhibitors for cancer

OncoArendi Therapeutics discloses new cancer treatments

Sage Therapeutics synthesizes novel GABA(A) receptor modulators

Amgen reports topline secondary endpoint results from TRINOVA-1 trial

D-Pharm reports data from phase II study of THR-18 in stroke patients treated with tPA

Ruga Corp. patents new B-raf kinase inhibitors

Chinese researchers prepare and test MKK1 inhibitors

Bayer completes acquisition of Dihon Pharmaceutical Group

NicOx reports development of NO donors

Repurposing of an approved glaucoma drug for the treatment of type 2 diabetes

CXCL10 gene polymorphism associated with malaria susceptibility in Ghanaian children

MedImmune to acquire tissue biomarker analysis company

EMA accepts Oleogel-S10 MAA for review

Terumo applies for approval of skeletal myoblast sheets

Kancera selects first candidate in ROR project

USAMRIID demonstrates in vitro activity of two HemispheRx drugs against Ebola virus

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...